NDC 85933-009-30
This exact product or package identity exists in FDA auxiliary data but is not present in the current primary NDC product table. The package identity is preserved; status rows are reported source observations, not medical conclusions.
- Requested NDC
- 85933-009-30
- Product root
- 85933-009
- Identity scope
- Package
- Primary current NDC product row
- Not present
NDC auxiliary status#
These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.
| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|---|---|---|---|---|---|---|
| compounder | package | 85933-009 | 85933-009-30 | COMPOUNDER | Outsourcing facility compounded drug report | 2026-1 | 2026-09-18 |
| compounder | package | 85933-009 | 85933-009-30 | COMPOUNDER | Outsourcing facility compounded drug report | 2026-1 | 2026-10-06 |
Compounder NDC reports#
| Establishment | FEI | Product NDC | Package NDC | Product | Active ingredients | Reporting period | Normalization |
|---|---|---|---|---|---|---|---|
| Wesley Pharmaceuticals | 85933-009 | 85933-009-30 | Thiamine HCl 100 mg.mL, Niacinamide 100 mg.mL, Riboflavin 5 Phosphate Sodium 2 mg.mL, Dexpanthenol 2 mg.mL, Pyridoxine HCl 2 mg.mL | 100 mg/1 mL; 1.908 mg/1 mL; 1.65 mg/1 mL; 100 mg/1 mL; 2 mg/1 mL | 2026-1 | valid | |
| Wesley Pharmaceuticals | 138312866 | 85933-009 | 85933-009-30 | Niacinamide; Riboflavin 5'-Phosphate Sodium Anhydrous; Pyridoxine Hydrochloride; Thiamine Hydrochloride; Dexpanthenol | 100 mg/1 mL; 1.908 mg/1 mL; 1.65 mg/1 mL; 100 mg/1 mL; 2 mg/1 mL | 2026-1 | valid |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.